AAOS2018: No difference between prolotherapy and sham saline in Osgood-Schlatter treatment .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2018;6(9):1038 adolescents with 50 knees affected by Osgood-Schlatter disease were randomized to three monthly treatments of either prolotherapy with a dextrose solution, or so sham prolotherapy with saline. Patients were assessed for function on the Victorian Institute of Sport Assessment (VISA) score after 1, 2 and 3 months. Results demonstrated no significant differences between groups at 1, 2, or 3 months, with a significant increase in scores from baseline for both groups.
Informe de la conferencia
Este informe de la ACE es un resumen de una presentación o resumen de conferencia. La información proporcionada ha limitado la capacidad de ofrecer una evaluación precisa del riesgo de sesgo o de la calidad general. Por favor, interprete los resultados con precaución ya que los ensayos pueden estar en curso y se pueden haber presentado resultados seleccionados.
¿Por qué se necesitaba ahora este estudio?
Osgood-Schlatter disease involves pain and swelling over the tibial tubercle in adolescents, particularly among those involved in sporting activities. Prolotherapy has been investigated for efficacy in various musculoskeletal ailments, though not in the setting of Osgood-Schlatter disease.
¿Cuál era la pregunta principal de la investigación?
In the treatment of adolescents with Osgood-Schlatter disease, how does efficacy and safety of prolotherapy with dextrose compare to sham prolotherapy with saline, assessed over 3 months of treatment?
- VISA scores did not significantly differ between the prolotherapy group and the sham group at either 1 month (76.9+/-20.4 vs. 72.6+/-22.2; p=0.508), 2 months (73.3+/-26.8 vs. 74.6+/-26.7; p=0.874), or 3 months (85.7+/-18.7 vs. 83.2+/-19.8; p=0.658).
- The degree of improvement from baseline after 1 month, 2 months, and 3 months was significant in each group.
¿Qué es lo que más debo recordar?
In the treatment of adolescents with Osgood-Schlatter disease, prolotherapy for 3 months with a dextrose solution demonstrated no significant difference in functional outcome when compared to sham prolotherapy.
¿Cómo afectará esto al cuidado de mis pacientes?
The results of this study suggest that prolotherapy with a dextrose solution may demonstrate no clinical advantage over saline for functional improvement in the management of adolescents with Osgood-Schlatter disease.
DESCARGO DE RESPONSABILIDAD
El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.
0 de 4 artículos mensuales GRATIS desbloqueados
